APA   Click to copy
D'Angelo, A., Sobhani, N., Bagby, S., Casadei-Gardini, A., & Roviello, G. (2020). Cabozantinib as a second-line treatment option in hepatocellular carcinoma. Expert Review Clinical Pharmacology, 13(6), 623–629. https://doi.org/10.1080/17512433.2020.1767591

Chicago/Turabian   Click to copy
D'Angelo, Alberto, Navid Sobhani, Stefan Bagby, Andrea Casadei-Gardini, and Giandomenico Roviello. “Cabozantinib as a Second-Line Treatment Option in Hepatocellular Carcinoma.” Expert Review Clinical Pharmacology 13, no. 6 (2020): 623–629.

MLA   Click to copy
D'Angelo, Alberto, et al. “Cabozantinib as a Second-Line Treatment Option in Hepatocellular Carcinoma.” Expert Review Clinical Pharmacology, vol. 13, no. 6, 2020, pp. 623–29, doi:10.1080/17512433.2020.1767591.

@article{alberto2020a,
  title = {Cabozantinib as a second-line treatment option in hepatocellular carcinoma},
  year = {2020},
  issue = {6},
  journal = {Expert Review Clinical Pharmacology},
  pages = {623-629},
  volume = {13},
  doi = {10.1080/17512433.2020.1767591},
  author = {D'Angelo, Alberto and Sobhani, Navid and Bagby, Stefan and Casadei-Gardini, Andrea and Roviello, Giandomenico}
}